Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

We and other groups have recently reported the potentiation by ribonucleotide reductase inhibitors such as hydroxyurea of the anti-human immunodeficiency virus type 1 (HIV-1) activity of purine and pyrimidine 2',3'-dideoxynucleosides in both resting and phytohemagglutinin-stimulated peripheral blood mononuclear cells. Little agreement prevails, however, as to the mechanism of the synergistic effects described. We report here that in phytohemagglutinin-stimulated peripheral blood mononuclear cells, two mechanisms exist for the potentiation of the anti-HIV-1 activity by low-dose hydroxyurea of the purine-based dideoxynucleoside 2',3'-dideoxyinosine and the pyrimidine-based dideoxynucleosides 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine. For 2',3'-dideoxyinosine, the enhancement arises from a specific depletion of dATP by hydroxyurea, resulting in a favorable shift of the 2',3'-dideoxyadenosine 5'-triphosphate/dATP ratio. For the pyrimidine dideoxynucleosides 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine, the more modest anti-HIV enhancement results from hydroxyurea-induced increases of pyrimidine kinase activities in the salvage pathway and, hence, increased 5'-phosphorylation of these drugs, while depletion of the corresponding deoxynucleoside 5'-triphosphates (dTTP and dCTP) plays no significant role.

Discovery, structure and biological activities of the cyclotides

The cyclotides are a family of small disulfide rich proteins that have a cyclic peptide backbone and a cystine knot formed by three conserved disulfide bonds. The combination of these two structural motifs contributes to the exceptional chemical, thermal and enzymatic stability of the cyclotides, which retain bioactivity after boiling. They were initially discovered based on native medicine or screening studies associated with some of their various activities, which include uterotonic action, anti-HIV activity, neurotensin antagonism, and cytotoxicity. They are present in plants from the Rubiaceae, Violaceae and Cucurbitaccae families and their natural function in plants appears to be in host defense: they have potent activity against certain insect pests and they also have antimicrobial activity. There are currently around 50 published sequences of cyclotides and their rate of discovery has been increasing over recent years. Ultimately the family may comprise thousands of members. This article describes the background to the discovery of the cyclotides, their structural characterization, chemical synthesis, genetic origin, biological activities and potential applications in the pharmaceutical and agricultural industries. Their unique topological features make them interesting from a protein folding perspective. Because of their highly stable peptide framework they might make useful templates in drug design programs, and their insecticidal activity opens the possibility of applications in crop protection.

New approaches to making the microenvironment of the female reproductive tract hostile to HIV

The studies presented in this review explore three distinct areas with potential for inhibiting HIV infection in women. Based on emerging information from the physiology, endocrinology and immunology of the female reproductive tract (FRT), we propose unique 'works in progress' for protecting women from HIV. Various aspects of FRT immunity are suppressed by estradiol during the menstrual cycle, making women more susceptible to HIV infection. By engineering commensal Lactobacillus to secrete the anti-HIV molecule Elafin as estradiol levels increase, women could be protected from HIV infection. Selective estrogen response modifiers enhance barrier integrity and enhance secretion of protective anti-HIV molecules. Finally, understanding the interactions and regulation of FRT endogenous antimicrobials, proteases, antiproteases, etc., all of which are under hormonal control, will open new avenues to therapeutic manipulation of the FRT mucosal microenvironment. By seeking new alternatives to preventing HIV infection in women, we may finally disrupt the HIV pandemic.

Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK

Background Prostate cancer (PCa) frequently relapses after hormone ablation therapy. Unfortunately, once progressed to the castration resistant stage, the disease is regarded as incurable as prostate cancer cells are highly resistant to conventional chemotherapy. Method We recently reported that the two natural compounds polysaccharopeptide (PSP) and Gamma-tocotrienols (γ-T3) possessed potent anti-cancer activities through targeting of CSCs. In the present study, using both prostate cancer cell line and xenograft models, we seek to investigate the therapeutic potential of combining γ-T3 and PSP in the treatment of prostate cancer. Result We showed that in the presence of PSP, γ-T3 treatment induce a drastic activation of AMP-activated protein kinase (AMPK). This was accompanied with inactivation of acetyl-CoA carboxylase (ACC), as evidenced by the increased phosphorylation levels at Ser 79. In addition, PSP treatment also sensitized cancer cells toward γ-T3-induced cytotoxicity. Furthermore, we demonstrated for the first time that combination of PSP and γ-T3 treaments significantly reduced the growth of prostate tumor in vivo. Conclusion Our results indicate that PSP and γ-T3 treaments may have synergistic anti-cancer effect in vitro and in vivo, which warrants further investigation as a potential combination therapy for the treatment of cancer.

Synthesis and exploration of novel curcumin analogues as anti-malarial agents

Curcumin, a major yellow pigment and active component of turmeric, has been shown to possess anti-inflammatory and anti-cancer activities. Recent studies have indicated that curcumin inhibits chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) Plasmodium falciparum growth in culture with an IC50 of not, vert, similar3.25 μM (MIC = 13.2 μM) and IC50 4.21 μM (MIC = 14.4 μM), respectively. In order to expand their potential as anti-malarials a series of novel curcumin derivatives were synthesized and evaluated for their ability to inhibit P. falciparum growth in culture. Several curcumin analogues examined show more effective inhibition of P. falciparumgrowth than curcumin. The most potent curcumin compounds 3, 6, and 11 were inhibitory for CQ-S P. falciparum at IC50 of 0.48, 0.87, 0.92 μM and CQ-R P. falciparum at IC50 of 0.45 μM, 0.89, 0.75 μM, respectively. Pyrazole analogue of curcumin (3) exhibited sevenfold higher anti-malarial potency against CQ-S and ninefold higher anti-malarial potency against CQ-R. Curcumin analogues described here represent a novel class of highly selective P. falciparum inhibitors and promising candidates for the design of novel anti-malarial agents.

Synthesis and exploration of novel curcumin analogues as anti-malarial agents

Curcumin, a major yellow pigment and active component of turmeric, has been shown to possess anti-inflammatory and anti-cancer activities. Recent studies have indicated that curcumin inhibits chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) Plasmodium falciparum growth in culture with an IC50 of similar to 3.25 mu M (MIC = 13.2 mu M) and IC50 4.21 mu M (MIC = 14.4 mu M), respectively. In order to expand their potential as anti-malarials a series of novel curcumin derivatives were synthesized and evaluated for their ability to inhibit P. falciparum growth in culture. Several curcumin analogues examined show more effective inhibition of P. falciparum growth than curcumin. The most potent curcumin compounds 3, 6, and 11 were inhibitory for CQ-S P. falciparum at IC50 of 0.48, 0.87, 0.92 mu M and CQ-R P. falcipartan at IC50 of 0.45 mu M, 0.89, 0.75 mu M, respectively. Pyrazole analogue of curcumin (3) exhibited sevenfold higher anti-malarial potency against CQ-S and ninefold higher anti-malarial potency against CQ-R. Curcumin analogues described here represent a novel class of highly selective P. falcipartan inhibitors and promising candidates for the design of novel anti-malarial agents. (C) 2007 Elsevier Ltd. All rights reserved.

Statistical and econometric analysis of the treatment of HIV/AIDS

The epidemic of HIV/AIDS in the United States is constantly changing and evolving, starting from patient zero to now an estimated 650,000 to 900,000 Americans infected. The nature and course of HIV changed dramatically with the introduction of antiretrovirals. This discourse examines many different facets of HIV from the beginning where there wasn't any treatment for HIV until the present era of highly active antiretroviral therapy (HAART). By utilizing statistical analysis of clinical data, this paper examines where we were, where we are and projections as to where treatment of HIV/AIDS is headed.

Chapter Two describes the datasets that were used for the analyses. The primary database utilized was collected by myself from an outpatient HIV clinic. The data included dates from 1984 until the present. The second database was from the Multicenter AIDS Cohort Study (MACS) public dataset. The data from the MACS cover the time between 1984 and October 1992. Comparisons are made between both datasets.

Chapter Three discusses where we were. Before the first anti-HIV drugs (called antiretrovirals) were approved, there was no treatment to slow the progression of HIV. The first generation of antiretrovirals, reverse transcriptase inhibitors such as AZT (zidovudine), DDI (didanosine), DDC (zalcitabine), and D4T (stavudine) provided the first treatment for HIV. The first clinical trials showed that these antiretrovirals had a significant impact on increasing patient survival. The trials also showed that patients on these drugs had increased CD4+ T cell counts. Chapter Three examines the distributions of CD4 T cell counts. The results show that the estimated distributions of CD4 T cell counts are distinctly non-Gaussian. Thus distributional assumptions regarding CD4 T cell counts must be taken, into account when performing analyses with this marker. The results also show the estimated CD4 T cell distributions for each disease stage: asymptomatic, symptomatic and AIDS are non-Gaussian. Interestingly, the distribution of CD4 T cell counts for the asymptomatic period is significantly below that of the CD4 T cell distribution for the uninfected population suggesting that even in patients with no outward symptoms of HIV infection, there exists high levels of immunosuppression.

Chapter Four discusses where we are at present. HIV quickly grew resistant to reverse transcriptase inhibitors which were given sequentially as mono or dual therapy. As resistance grew, the positive effects of the reverse transcriptase inhibitors on CD4 T cell counts and survival dissipated. As the old era faded a new era characterized by a new class of drugs and new technology changed the way that we treat HIV-infected patients. Viral load assays were able to quantify the levels of HIV RNA in the blood. By quantifying the viral load, one now had a faster, more direct way to test antiretroviral regimen efficacy. Protease inhibitors, which attacked a different region of HIV than reverse transcriptase inhibitors, when used in combination with other antiretroviral agents were found to dramatically and significantly reduce the HIV RNA levels in the blood. Patients also experienced significant increases in CD4 T cell counts. For the first time in the epidemic, there was hope. It was hypothesized that with HAART, viral levels could be kept so low that the immune system as measured by CD4 T cell counts would be able to recover. If these viral levels could be kept low enough, it would be possible for the immune system to eradicate the virus. The hypothesis of immune reconstitution, that is bringing CD4 T cell counts up to levels seen in uninfected patients, is tested in Chapter Four. It was found that for these patients, there was not enough of a CD4 T cell increase to be consistent with the hypothesis of immune reconstitution.

In Chapter Five, the effectiveness of long-term HAART is analyzed. Survival analysis was conducted on 213 patients on long-term HAART. The primary endpoint was presence of an AIDS defining illness. A high level of clinical failure, or progression to an endpoint, was found.

Chapter Six yields insights into where we are going. New technology such as viral genotypic testing, that looks at the genetic structure of HIV and determines where mutations have occurred, has shown that HIV is capable of producing resistance mutations that confer multiple drug resistance. This section looks at resistance issues and speculates, ceterus parabis, where the state of HIV is going. This section first addresses viral genotype and the correlates of viral load and disease progression. A second analysis looks at patients who have failed their primary attempts at HAART and subsequent salvage therapy. It was found that salvage regimens, efforts to control viral replication through the administration of different combinations of antiretrovirals, were not effective in 90 percent of the population in controlling viral replication. Thus, primary attempts at therapy offer the best change of viral suppression and delay of disease progression. Documentation of transmission of drug-resistant virus suggests that the public health crisis of HIV is far from over. Drug resistant HIV can sustain the epidemic and hamper our efforts to treat HIV infection. The data presented suggest that the decrease in the morbidity and mortality due to HIV/AIDS is transient. Deaths due to HIV will increase and public health officials must prepare for this eventuality unless new treatments become available. These results also underscore the importance of the vaccine effort.

The final chapter looks at the economic issues related to HIV. The direct and indirect costs of treating HIV/AIDS are very high. For the first time in the epidemic, there exists treatment that can actually slow disease progression. The direct costs for HAART are estimated. It is estimated that the direct lifetime costs for treating each HIV infected patient with HAART is between $353,000 to $598,000 depending on how long HAART prolongs life. If one looks at the incremental cost per year of life saved it is only $101,000. This is comparable with the incremental costs per year of life saved from coronary artery bypass surgery.

Policy makers need to be aware that although HAART can delay disease progression, it is not a cure and HIV is not over. The results presented here suggest that the decreases in the morbidity and mortality due to HIV are transient. Policymakers need to be prepared for the eventual increase in AIDS incidence and mortality. Costs associated with HIV/AIDS are also projected to increase. The cost savings seen recently have been from the dramatic decreases in the incidence of AIDS defining opportunistic infections. As patients who have been on HAART the longest start to progress to AIDS, policymakers and insurance companies will find that the cost of treating HIV/AIDS will increase.

A cocktail of thermally stable, chemically synthesized capture agents for the efficient detection of anti-gp41 antibodies from human sera and techniques

This thesis reports on a method to improve in vitro diagnostic assays that detect immune response, with specific application to HIV-1. The inherent polyclonal diversity of the humoral immune response was addressed by using sequential in situ click chemistry to develop a cocktail of peptide-based capture agents, the components of which were raised against different, representative anti-HIV antibodies that bind to a conserved epitope of the HIV-1 envelope protein gp41. The cocktail was used to detect anti-HIV-1 antibodies from a panel of sera collected from HIV-positive patients, with improved signal-to-noise ratio relative to the gold standard commercial recombinant protein antigen. The capture agents were stable when stored as a powder for two months at temperatures close to 60°C.

Avaliação do impacto da gestão de uma organização da sociedade civil de interesse público nas ações desenvolvidas no programa de controle de tuberculose em unidades de saúde em Duque de Caxias.

Entre os anos de 2009 a 2012 o município de Duque de Caxias realizou uma parceria com uma organização social civil de interesse público (OSCIP) para gerir seis unidades mistas de saúde. A tuberculose (TB) é um grave problema de saúde pública no Brasil. Em Duque de Caxias o Programa de Controle de Tuberculose necessitava ampliação e descentralização para o maior acesso à população. Objetivo: Este estudo teve como objetivo avaliar o impacto da gestão de uma OSCIP em seis unidades de saúde do município de Duque de Caxias, Estado do Rio de Janeiro, tendo como base os resultados alcançados no Programa de Controle da Tuberculose (PCT). Metodologia: Realizou-se uma pesquisa quantitativa, descritiva, de evolução temporal dos indicadores do PCT, com base em dados secundários gerados através do banco de dados do SINAN/DC, assim como a análise documental do Livro de Registros das Baciloscopias e Culturas do PCT. Levantamento na literatura sobre o tema. Também através de pesquisa eletrônica pela internet realizou-se um levantamento na literatura sobre o tema. Resultado e Discussão: A parceria com a OSCIP possibilitou a descentralização do Programa de Controle da Tuberculose para os quatro distritos do município. Na análise dos indicadores observou-se melhor desempenho das unidades de saúde sob a gerência da OSCIP em alguns indicadores de processo, como realização do exame anti-HIV e percentual de baciloscopias realizadas. Quanto aos indicadores de resultado, em ambos os tipos de gerência, observou-se baixa atuação no alcance das metas nacionais. Conclusão: Apesar das limitações metodológicas, como o curto período de tempo da análise dos indicadores, a utilização de dados secundários (SINAN), o presente estudo permitiu um olhar inicial das vantagens, desvantagens e limitações da parceria com uma OSCIP no serviço público. Serão necessários novos estudos com período maior de tempo além da inclusão de outros indicadores

S-DABO 类衍生物及AZT-氟喹喏酮类偶联物体外抗HIV 活性及机制研究

本论文由2 个相对独立的部分组成: S-DABO 类衍生物体外抗HIV 活性及 其机制研究和AZT－氟喹喏酮类偶联物体外抗HIV-1 活性及其机制研究。 HIV 逆转录酶抑制剂一直是抗HIV 药物研发的热点。该类抑制剂靶定在病 毒复制周期早期，为HAART 疗法提供了很多新的药物组合。目前FDA 批准上 市的逆转录酶抑制剂虽然有很多，但由于较严重的毒副作用、HIV 病毒易变异、 耐药性的出现等问题还需要开发更多的新的逆转录酶抑制剂。本论文对23 个 S-DABO 类化合物和8 个AZT－氟喹喏酮类偶联物的体外抗HIV 活性进行检 测，并对其中活性较高的化合物进行靶点和机制研究。 23 个S-DABO 类化合物采用对C8166 细胞的毒性试验，对HIV-1ⅢB 诱导的 合胞体形成的抑制试验和对HIV-1ⅢB 急性感染的MT-4 细胞的保护试验进行抗 HIV-1 活性初步筛选。试验结果发现所有化合物均对多种HIV 宿主细胞毒性小， 其中22 个化合物具有抗HIV-1 活性，特别是化合物RZK-4 和RZK-5，其对 HIV-1ⅢB 诱导的合胞体形成的SI 值（Selective index）分别为>16666 和>38462； RZK-4 和RZK-5 对HIV-1ⅢB 急性感染的MT-4 细胞的保护的SI 值分别为2666.67 和2150.54，与相应的阳性对照药品NVP（Nevirapine）的SI 值相接近。以p24 抗原水平为指标，对其中20 个化合物的抗HIV-1 活性进行确证，发现这20 个 化合物均能抑制 HIV-1ⅢB p24 抗原的产生，其中RZK-4 和RZK-5 的EC50 值分 别为5.93 和5.74ng/ml，比相应的阳性对照药品NVP（Nevirapine）的EC50 值 要低（27.3ng/ml）。这些化合物对试验株HIV-1MN、临床分离株HIV-1KM018、非 核苷类抑制剂耐药株HIV-1ⅢB A17 也有较好的抑制效果。但这23 个S-DABO 类化合物对HIV-2 病毒株均无抑制作用。通过检测化合物对感染与未感染细胞的 融合的抑制、对HIV-1 逆转录酶和蛋白酶活性的抑制、对慢性感染H9 细胞 （H9/HIV-1ⅢB）中病毒复制的抑制等试验来探讨化合物的抗HIV-1 机制。结果 显示：有20 个化合物对HIV-1 蛋白酶（PR）有抑制作用，其中有17 个化合物 对HIV-1 逆转录酶（RT）有抑制作用；但所有化合物均不能抑制感染与未感染 细胞的融合，也不能抑制慢性感染H9 细胞中病毒的复制。试验结果表明，这 23 个S-DABO 类化合物主要通过抑制HIV-1 逆转录酶来发挥作用，它们是典型 的非核苷类RT 抑制剂。 8 个AZT－氟喹喏酮类偶联物采用对C8166 细胞的毒性试验，对HIV-1ⅢB 诱导的合胞体形成的抑制试验和对HIV-1ⅢB急性感染的MT-4 细胞的保护试验 进行抗HIV-1 活性初步筛选。试验结果发现其中2 个化合物SRLZ 和SROZ 有 较显著的抗HIV-1 活性，其对HIV-1ⅢB诱导的合胞体形成抑制的SI 值分别为 >41667 和>105263；对HIV-1ⅢB 急性感染的MT-4 细胞的保护的SI 值分别为 30162 和 6368，与AZT（Zidothymidine）的SI 值相近似。以p24 抗原水平为 指标，对其抗HIV-1活性进行确证，发现化合物SRLZ和SROZ均能抑制HIV-1ⅢB p24 抗原的产生，其EC50 值分别为 0.71 和2.1ng/ml,比相应的阳性对照药品AZT 的EC50 值要低（3.5ng/ml）。化合物SRLZ 和SROZ 对临床分离株HIV-1KM018 也有较好的抑制活性，其EC50 值分别为1.4 和22ng/ml。通过检测化合物对慢 性感染H9 细胞（H9/HIV-1ⅢB）中病毒复制的抑制试验来探讨化合物的抗HIV-1 机制，结果表明化合物SRLZ 和SROZ 均不能抑制慢性感染H9 细胞中病毒的 复制。通过检测化合物对金黄色葡萄球菌的抑制作用来检测其抗菌活性，化合 物SRLZ 和SROZ 对金黄色葡萄球菌有较好的抑制作用，其MIC（Minimum inhibitory concentration）值分别为14.65 和7.32μg/ml，与其相应的阳性对照药 物的MIC 值相类似。试验结果表明：药物—药物偶连这种化学修饰方法并没有 改变AZT－氟喹喏酮类偶联物的抗HIV 作用靶点，但也没有较大地影响到其体 外抗病毒活性和抗微生物活性。

蒲葵籽提取物体外抗HIV-1活性及机制的初步研究

下载PDF阅读器目的 研究蒲葵籽提取物的体外抗HIV-1活性,对有活性粗提物进行初步机制研究.方法 采用细胞毒性、合胞体抑制、HIV-1感染细胞保护实验和HIV-1 p24抗原测定等实验对蒲葵籽提取物体外抗HIV-1活性进行筛选和确认;采用重组HIV-1逆转录酶和蛋白酶活性抑制实验,融合阻断实验初步探讨活性粗提物的作用机制.结果 蒲葵籽的醋酸乙酯(P3)提取物具有较强的体外抗HIV-1活性,P3抑制HIV-1诱导C8166细胞形成合胞体的EC50为5.64 pg/mL,对C8166细胞的毒性较小,CC50大于200 μg/mL,治疗指数(T1)大于35.46;P3抑制HIV-1急性感染中p24抗原表达的EC50为23.04 μg/mL,抑制正常C8166细胞与慢性感染细胞Hg/HIV-1-B融合的EC50为8.00 μg/mL;P3在质量浓度为200μg/mL时,对HIV-1逆转录酶的抑制率为28.86%;P3抑制重组HIV-1蛋白酶活性的EC50为1.77μg/mL.结论 蒲葵籽的醋酸乙酯提取物(P3)具有较强的体外抗HIV-1活性,其作用机制可能主要为阻断病毒进入和抑制HIV-1蛋白酶活性.

藤三七中一个新黄烷醇和抗HIV活性成分

利用各种色谱(硅胶和凝胶)方法,从藤三七[Boussingaultia gracilis Miers var.pseudobaselloides Bailey]的70%(体积分数)的乙醇提取物中分离得到2个黄烷醇类化合物(1,2)和4个黄酮类化合物(3～6).采用UV,IR,MS 和1D,2D NMR方法,分别鉴定出如下化合物: 7-羟基-5-甲氧基-8-甲基-6-甲酰基-3,4-黄烷二醇,命名为藤三七醇A(1);4,7-二羟基-5-甲氧基-8-甲基-6-甲酰基黄烷(2);7-O-methylunonal(3);5,7-二羟基-6,8-二甲基-2-苯基-4H-1-苯并吡喃-4-酮(4);Desmosflavone(5)和Demethoxymatteucinol(6).其中化合物1是一个新的黄烷二醇化合物,化合物2～6为首次从该植物中分离得到.抗HIV-1活性筛选结果表明: 化合物1,2,5,6对HIV-1诱导合胞体的形成具有一定的抑制作用,其半数有效浓度(EC50)分别为45.09,48.73,55.47 和 82.75 μmol/L,治疗指数(TI)分别为1.41,1.20,7.15 和》8.51.

点柄乳牛肝菌子实体中抗HIV-1活性成分

目的 研究点柄乳牛肝菌的化学成分,并对分离鉴定的化合物进行抗HIV-1的活性研究.方法 将野外采集的点柄乳牛肝菌子实体用溶剂提取,采用硅胶柱色谱进行分离,通过波谱技术(NMR,MS,IR等)对结构进行鉴定.结果 分离鉴定了9个化合物,分别为:酒渣碱(Ⅰ)、5a,8a-过氧麦角甾-6,22-二烯-3β-醇(Ⅱ)、麦角甾-5,7,22-三烯-3β-醇(Ⅲ)、麦角甾-5,7,22-三烯-3β-O-β-D-吡喃葡萄糖苷(Ⅳ)、尿嘧啶(Ⅴ))、硫代乙酸酐(Ⅵ)、硬脂酸(Ⅶ)、3-吡啶甲酸(Ⅷ)和D-阿洛糖醇(Ⅸ).结论 化合物Ⅰ为首次从高等真菌中分离.经生物活性测试,该化合物具有抗HIV-1活性,对C8166细胞的毒性较小,CC50为87.86 μg/mL,对HIV-1诱导C8166细胞形成合胞体抑制的EC50为7.27 μg/mL,治疗指数(TI值)为12.09.

槐花提取化合物K3体外抗HIV-1活性的研究

目的:研究槐花提取化合物K3的体外抗HIV-1活性,并对其抗HIV-1机制进行初步探讨.方法:采用MTT比色法检测化合物对各种细胞的毒性.用合胞体形成计数法,p24抗原捕获ELISA法及RT-PCR等多种方法研究化合物体外抗HIV-1活性.结论:槐花提取化合物K3体外有较好的抗HIV-1活性,能够抑制病毒实验株(HIV-1ⅢB,耐药株(HIV-1 74v)和临床分离株(HIV-1KM018)等多种病毒株的复制,且其作用机制是多靶点的,不仅可以抑制病毒的进入,还可以抑制HIV-1逆转录酶活性.

核糖体失活蛋白抗HIV-1作用的研究进展

核糖体失活蛋白(RIPs)抗HIV-1活性研究已有十几年的历史。RIPs类化合物代表了抗HIV/AIDS天然产物或先导化合物发展的一个重要方向。本文从介绍RIPs的酶活性及其抗HIV-1活性入手,对RIPs抗HIV-1的可能机制,从与RIPs酶活性的关系、诱导HIV-1感染细胞的凋亡及相应的信号转导、诱发活性氧的产生,以及对HIV-1整合酶的抑制作用等几个方面做了较详尽的阐述,并对RIPs的结构修饰和抗HIV-1构效关系进行了综述。对RIPs类化合物在抗病毒领域进行深入而系统地研究,能拓宽其在抗HIV/AIDS临床上的进一步应用。